---
layout: default
title: Tinidazole
parent: 僅模型預測 (L5)
nav_order: 1229
evidence_level: L5
indication_count: 10
---

# Tinidazole
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Tinidazole: From Antiprotozoal/Antimicrobial Infection to Postmenopausal Atrophic Vaginitis

## One-Sentence Summary

> Tinidazole is a 5-nitroimidazole antimicrobial agent, pharmacologically known for treating anaerobic bacterial and protozoal infections (e.g., trichomoniasis, giardiasis, amebiasis), though no TFDA-approved indication record exists in this evidence pack.
> The TxGNN model predicts it may be effective for **Postmenopausal Atrophic Vaginitis**, with a very high similarity score, but **currently no clinical trials or published literature support this specific prediction**.
> The evidence level is the lowest tier (L5 — model prediction only), and the drug's own repurposing rationale flags this as a likely knowledge-graph co-occurrence artifact rather than a genuine pharmacological relationship.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in TFDA licensing records (drug is not marketed in Taiwan). Based on general pharmacological classification, tinidazole is a 5-nitroimidazole used for anaerobic bacterial/protozoal infections (trichomoniasis, giardiasis, amebiasis) |
| Predicted New Indication | Postmenopausal Atrophic Vaginitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data for tinidazole is not available (data gap). Based on general pharmacological knowledge, tinidazole is a 5-nitroimidazole prodrug that, once activated by the ferredoxin-reduction system in anaerobic bacteria and protozoa, generates cytotoxic free radicals that damage microbial DNA. It is active against *Trichomonas vaginalis*, *Giardia*, and *Entamoeba histolytica*.

Postmenopausal atrophic vaginitis, however, is primarily caused by **estrogen deficiency after menopause**, leading to vaginal mucosal thinning and reduced lubrication — a non-infectious, hormone-driven pathology. Tinidazole has no known estrogenic, mucosal-repair, or hormonal activity, and its antimicrobial mechanism does not directly address this underlying cause.

**Assessment provided in the evidence pack itself explicitly flags this as a low-confidence prediction**: the high TxGNN score likely reflects knowledge-graph node co-occurrence (e.g., "vaginal disease" nodes linked to "antibiotic treatment for vaginal infection" edges) rather than a true pharmacological relationship. No clinical trials or literature currently exist to support tinidazole's use in postmenopausal atrophic vaginitis. This prediction should be treated as a hypothesis-generating signal only, not a basis for further clinical development at this time.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## US Market Information

No approved drug licenses are currently recorded for tinidazole in this jurisdiction (`taiwan_regulatory.total_licenses = 0`, market status: 未上市 / Not Marketed). No product-level marketing data is available for review.

---

## Safety Considerations

Please refer to the package insert for safety information.

*(All safety fields — key warnings, contraindications, and drug-drug interactions — are currently data gaps in this evidence pack. Notably, DG001 flags TFDA package insert warnings/contraindications as a **Blocking** data gap that must be resolved before any safety pre-screening (S1) can proceed.)*

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
- The TxGNN score for postmenopausal atrophic vaginitis is high (99.93%), but this is unsupported by any clinical trial or literature evidence (L5), and the evidence pack's own mechanistic analysis suggests the prediction is likely a knowledge-graph artifact rather than a real pharmacological signal. There is no biologically coherent link between tinidazole's antimicrobial mechanism and estrogen-deficiency-driven mucosal atrophy.

**To proceed, the following is needed:**
- TFDA package insert data (warnings/contraindications) — currently a **Blocking** data gap (DG001) that prevents even preliminary safety screening
- Confirmed mechanism of action (MOA) data (DG002)
- If this indication is to be pursued further, dedicated mechanistic or preclinical studies specifically linking tinidazole to vaginal mucosal/estrogen pathways would be required, as none currently exist

**Note on alternative candidates:** Among the 10 TxGNN-predicted indications in this evidence pack, **rank 5 (AIDS)** stands out with meaningfully stronger evidence — L3 evidence level, 1 supporting clinical trial (NCT03412071, microbiome-focused HIV susceptibility intervention), and 16 literature references, mostly relating to tinidazole's established role in treating anaerobic/protozoal co-infections (e.g., trichomoniasis, amebiasis) in HIV/AIDS populations. This indication may represent a more promising "Research Question"-stage candidate than the top-ranked prediction and could warrant a separate, dedicated evaluation report.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

